Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses alternative options for the treatment for chronic lymphocytic leukemia (CLL). Similar to idelalisib are the SYK inhibitors which are awaiting approval. There are also BTK inhibitors, such as ibrutinib. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
©2022 SHIVAWATER™ by General Intelligent Services and Productions, LLC., authorized by Bassocco, Est. 1992, first brand in the world to bottle and distribute alkaline water, all rights reserved. If you use our website in any form, it means you have accepted our Terms and Conditions. Questions? Contact us.